Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT-HER2-IV neoadjuvant trastuzumab deruxtecan vs taxane-carboplatin-trastuzumab-pertuzumab in HER2-positive early breast cancer
2024-514458-61-01Phase 2Authorised
- Sponsor
- Westdeutsche Studiengruppe
- Start
- Oct 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of trastuzumab deruxtecan in breast cancer (4 arms), sponsored by Westdeutsche Studiengruppe. Primary endpoints: Grade ≥3 adverse drug reactions (T-DXd 18 weeks vs SoC 18 weeks), 3-year distant disease-free survival (dDFS) in T-DXd neoadjuvant monotherapy and 2 more. Planned start Oct 2024; status: authorised.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-514458-61-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514458-61-01.